神经元多不和脂肪酸在ALS/FTD中具有保护作用
Ashling Giblin1,2,3, Alexander J Cammack1,4, Niek Blomberg5
1UK Dementia Research Institute, UCL, London, UK.
Nature neuroscience
|February 25, 2025
概括
研究人员发现,脂肪酸代谢在肌缩侧面硬化症 (ALS) 和前性痴呆症 (FTD) 中降低了. 增加神经元中的多不和脂肪酸 (PUFA) 改善了模型中的生存率,这表明了潜在的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 生物化学 生物化学
背景情况:
- C9orf72重复扩张是ALS/FTD的主要遗传原因.
- 改变的脂质代谢与神经退行性疾病有关.
- 了解ALS/FTD的分子途径对于开发治疗方法至关重要.
研究的目的:
- 研究脂肪酸和脂质代谢在C9orf72相关的ALS/FTD中的作用.
- 在ALS/FTD模型和患者组织中识别特定的脂质变化.
- 探索多不和脂肪酸 (PUFA) 在ALS/FTD中的治疗潜力.
主要方法:
- 在Drosophila模型中对C9orf72重复扩张的转录基因分析.
- 果菌,iPS细胞神经元和死后脑组织的脂质分析.
- 在Drosophila和iPS细胞中进行基因操纵 (脂肪酸脱酸酶的过度表达).
- 对PUFA补充剂和基因干预措施的生存和神经元死亡的评估.
主要成果:
- 在C9orf72 ALS/FTD模型和人体组织中观察到减少脂肪酸和脂质代谢的转录基因特征.
- 确定了含有多不和脂肪酸 (PUFA) 的脂蛋白的特定减少.
- 将PUFA给提供了适度的生存益处.
- 脂肪酸脱酶的神经过度表达显著延长了的寿命,并保护了iPS细胞神经元免于死亡.
结论:
- 神经细胞脂肪酸和与ALS/FTD病变发生有关.
- 增加神经元PUFA水平代表了对ALS/FTD的有前途的治疗策略.
- 准脂质代谢途径可能为神经退行性疾病提供新的治疗途径.
相关概念视频
Role of Neurotransmitters in Memory
379
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
379
Alzheimer's Disease: Overview
422
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
422
Glial Cells
86.1K
Overview
86.1K
Neural Regulation
39.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.1K
Amyloid Fibrils
9.2K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.2K
Alzheimer's Disease: Treatment
147
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
147


